Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 12/20 | 0.59 |
| ▸ | PARP1 | P09874 | 6/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014299 | 0.83 | PARP1 (0.67) | TNKSPARP1TNKS2 | |
| SCHEMBL15775395 | 0.83 | PARP1 (0.67) | TNKSPARP1TNKS2 | |
| SCHEMBL15569241 | 0.82 | PARP1 (0.73) | TNKSPARP1TNKS2 | |
| SCHEMBL30160687 | 0.82 | TNKS (0.58) | TNKSPIM1 | |
| SCHEMBL28924649 | 0.82 | TNKS (0.58) | TNKSPIM1 | |
| SCHEMBL4766919 | 0.80 | PARP1 (0.73) | TNKSPARP1TNKS2 | |
| SCHEMBL15776266 | 0.79 | PARP1 (0.69) | TNKSPARP1TNKS2 | |
| SCHEMBL15775412 | 0.79 | TNKS (0.65) | TNKSPARP1TNKS2 | |
| SCHEMBL15775813 | 0.78 | TNKS (0.56) | TNKSPARP1 | |
| SCHEMBL15775564 | 0.78 | TNKS (0.60) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TNKS 1771/4885PARP1 2477/4885PIM1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.